- Stocks
- Pharma & Healthcare
- HALEOS LABS
HALEOS LABS share price
NSE: HALEOSLABSPharma & HealthcareBiotechnology
HALEOS LABS at a glance
HALEOS LABS (NSE: HALEOSLABS) closed at ₹1,622.00 on 22 Oct 2026, up 2.33% on the day. With a market capitalisation of ₹490 Cr, it ranks 1797th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 28.3× trailing earnings, against a return on equity of 10.2% in FY25. Over the past year the share price has risen 44.8%. Its 52-week range is ₹1,091.10 (30 Jan 2026) to ₹1,774.00 (11 May 2026); the last close is 8.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹73 Cr (−11.6% year on year) and net profit ₹2 Cr (−58.0%), on a consolidated basis. Promoters held 72.11% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹490 CrRank 1797 on NSE
- P/E (trailing)
- 28.3×
- Price to book
- 1.66×FY25
- EPS (TTM)
- ₹52.27to Q1 FY27
- ROE
- 10.2%FY25
- ROCE
- 14.1%FY25
- Debt to equity
- 0.43FY25
- Net profit margin
- 5.4%FY25
- Book value / share
- ₹650.15FY25
- Dividend payout
- 2.3%FY25
- 52-week high
- ₹1,774.0011 May 2026
- 52-week low
- ₹1,091.1030 Jan 2026
- 1-year return
- +44.8%
- RSI (14-day)
- 64.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.33% | +3.5% | +9.2% | +4.7% | +44.8% |
HALEOS LABS quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹78 Cr | ₹85 Cr | ₹89 Cr | ₹83 Cr | ₹81 Cr | ₹95 Cr | ₹75 Cr | ₹73 Cr |
| Revenue YoY | +13.3% | +17.4% | −1.0% | −10.9% | +3.7% | +12.0% | −15.7% | −11.6% |
| Net profit | ₹3 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹7 Cr | ₹0 Cr | ₹2 Cr |
| Net profit YoY | — | +17.7% | −46.2% | −38.3% | +94.8% | +37.1% | −90.2% | −58.0% |
| Net margin | 4.2% | 5.7% | 3.9% | 5.3% | 7.9% | 7.0% | 0.5% | 2.5% |
| EPS | ₹15.46 | ₹18.08 | ₹9.83 | ₹13.75 | ₹20.19 | ₹21.89 | ₹1.44 | ₹8.75 |
HALEOS LABS financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹261 Cr | ₹266 Cr | ₹350 Cr | ₹316 Cr | ₹306 Cr | ₹345 Cr |
| Operating profit | ₹15 Cr | ₹20 Cr | ₹20 Cr | ₹14 Cr | ₹10 Cr | ₹26 Cr |
| Net profit | ₹10 Cr | ₹14 Cr | ₹25 Cr | ₹11 Cr | ₹6 Cr | ₹19 Cr |
| EPS (₹) | ₹34.00 | ₹45.00 | ₹84.00 | ₹38.00 | ₹30.00 | ₹67.00 |
| Cash from operations | ₹15 Cr | ₹35 Cr | −₹11 Cr | ₹15 Cr | ₹24 Cr | ₹34 Cr |
| Total debt | ₹37 Cr | ₹39 Cr | ₹40 Cr | ₹55 Cr | ₹33 Cr | ₹18 Cr |
| Shareholders' equity | ₹116 Cr | ₹129 Cr | ₹152 Cr | ₹169 Cr | ₹177 Cr | ₹197 Cr |
HALEOS LABS shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.41% | 71.41% | 71.41% | 71.80% | 72.11% | 72.11% |
| Domestic institutions | — | — | 0.03% | 0.29% | 0.30% | 0.31% |
| Non-institutions | 28.59% | 28.56% | 28.57% | 27.91% | 27.60% | 27.58% |
HALEOS LABS vs peers
The listed Pharma & Healthcare companies nearest to HALEOS LABS by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| HSILHemant Surgical | — | — | — | ₹551 Cr | — | — |
| HALEOSLABSHALEOS LABS | ₹1,622.00 | +2.33% | +44.8% | ₹490 Cr | 28.3 | — |
| PREVESTPrevest Denpro | — | — | — | ₹472 Cr | — | — |
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
| ALBERTDAVDAlbert David | ₹780.50 | +1.95% | −1.0% | ₹445 Cr | — | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| JENBURPHJenburkt Pharma | ₹865.50 | −2.76% | — | ₹382 Cr | 11 | — |
Ask anything about HALEOS LABS
Pivot answers on the live chart with evidence you can check, and tests strategies against HALEOSLABS's own history. Try: “Why has HALEOSLABS moved over the last three months?” · “Backtest a 50-day moving-average crossover on HALEOSLABS over five years” · “Compare HALEOSLABS with HSIL on margins and valuation”
Frequently asked questions about HALEOS LABS
What is the share price of HALEOS LABS today?
HALEOS LABS (NSE: HALEOSLABS) last closed at ₹1,622.00 on 22 Oct 2026. Its 52-week high is ₹1,774.00 and its 52-week low is ₹1,091.10.
What is the market cap of HALEOS LABS?
HALEOS LABS's market capitalisation is ₹490 Cr (₹490 Cr) at the 22 Oct 2026 close, ranking 1797th among the NSE companies Pivot tracks.
What is the P/E ratio of HALEOS LABS?
HALEOS LABS trades at a trailing P/E of 28.3.
What is the ROE and ROCE of HALEOS LABS?
Return on equity was 10.2% in FY25 and return on capital employed was 14.1% in FY25 (consolidated figures).
Is HALEOS LABS a debt-free company?
No. HALEOS LABS's debt-to-equity ratio was 0.43 in FY25, with total debt of ₹18 Cr.
What were HALEOS LABS's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), HALEOS LABS reported revenue of ₹73 Cr, −11.6% year on year, and net profit of ₹2 Cr, −58.0% year on year.
How has HALEOS LABS stock performed over the last year?
HALEOS LABS's share price has risen 44.8% over the past year, +4.7% over three months and +9.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of HALEOS LABS?
As of 30 Jun 2026: promoters 72.11%, domestic institutions 0.31%, non-institutions 27.58%.
Who are HALEOS LABS's competitors?
The listed Pharma & Healthcare companies closest to HALEOS LABS by market cap are Hemant Surgical, Prevest Denpro, Asarfi Hospital, Albert David, Transchem and Jenburkt Pharma.
Is HALEOS LABS a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out HALEOS LABS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HALEOSLABS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text